Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
alpha1H in NMIBC Awaiting TURB
NCT03560479Phase 2Unknown
- Sponsor
- Hamlet Pharma
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- Albumin, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alpha1-oleate in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by Hamlet Pharma. Primary endpoints: Safety as Adverse Events Profile, Efficacy as Cell Shedding and 1 more. Status: unknown.
02
Drugs
alpha1-oleate
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03560479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560479.